This is intended for US audiences only.

Thank you for your interest in the PURPOSE 2 study results.

1. HIVR4P 2024 PURPOSE 2 Late-Breaker Oral Presentation: “Twice-Yearly Lenacapavir for HIV Prevention in Cisgender Gay, Bisexual, and Other Men, Transgender Women, Transgender Men, and Gender-Nonbinary People who Have Sex With Partners Assigned Male at Birth: Interim Analysis Results From the PURPOSE 2 Study​” as presented by Dr. Colleen F Kelley on October 8, 2024
1. We have also created a short Graphical Summary of the above presentation
   
   
2. HIVR4P 2024 PURPOSE 2 Demographics Oral Presentation: “Global racial, ethnic, and gender diversity among participants enrolled in the PURPOSE 2 trial of lenacapavir for pre-exposure prophylaxis” as presented by Dr. Jorge Gallardo-Cartagena on October 8, 2024
   
   
3. For information about the recent press release on “Gilead Signs Royalty-Free Voluntary Licensing Agreements with Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries” published on October 2, 2024, please visit https://www.gilead.com/news/news-details/2024/gilead-signs-royalty-free-voluntary-licensing-agreements-with-six-generic-manufacturers-to-increase-access-to-lenacapavir-for-hiv-prevention-in-high-incidence-resource-limited-countries
   
   
4. For information about “Access Planning in High-Incidence, Resource-Limited Countries for Lenacapavir for HIV Prevention” please visit https://www.gilead.com/company/company-statements/2024/updated-statement-on-access-planning-in-high-incidence-resource-limited-countries-for-lenacapavir-for-hiv-prevention

5. For additional information about the PURPOSE program, including other PURPOSE studies, please visit www.purposestudies.com